1.
Safety and efficacy of MVA85A, a new tuberculosis vaccine, in infants previously vaccinated with BCG: a randomised, placebo-controlled phase 2b trial
by Tameris, Michele D, Dr
The Lancet (British edition), 2013, Vol.381 (9871), p.1021-1028
2.
Construction, characterization and preclinical evaluation of MTBVAC, the first live-attenuated M. tuberculosis -based vaccine to enter clinical trials
by Arbues, Ainhoa
Vaccine, 2013, Vol.31 (42), p.4867-4873
3.
A multistage tuberculosis vaccine that confers efficient protection before and after exposure
by Aagaard, Claus
Nature medicine, 2011, Vol.17 (2), p.189-194
4.
First-in-human trial of the post-exposure tuberculosis vaccine H56:IC31 in Mycobacterium tuberculosis infected and non-infected healthy adults
by Luabeya, Angelique Kany Kany
Vaccine, 2015, Vol.33 (33), p.4130-4140
5.
Safety and immunogenicity of a candidate tuberculosis vaccine MVA85A delivered by aerosol in BCG-vaccinated healthy adults: a phase 1, double-blind, randomised controlled trial
by Satti, Iman, PhD
The Lancet infectious diseases, 2014, Vol.14 (10), p.939-946
6.
7.
8.
Safety and immunogenicity of candidate vaccine M72/AS01E in adolescents in a TB endemic setting
by Penn-Nicholson, Adam
Vaccine, 2015, Vol.33 (32), p.4025-4034
9.
A novel liposomal adjuvant system, CAF01, promotes long-lived Mycobacterium tuberculosis -specific T-cell responses in human
by van Dissel, Jaap T
Vaccine, 2014, Vol.32 (52), p.7098-7107
10.
Improvement of BCG protective efficacy with a novel chimpanzee adenovirus and a modified vaccinia Ankara virus both expressing Ag85A
by Stylianou, E
Vaccine, 2015, Vol.33 (48), p.6800-6808
11.
Nanoparticle conjugation and pulmonary delivery enhance the protective efficacy of Ag85B and CpG against tuberculosis
by Ballester, Marie
Vaccine, 2011, Vol.29 (40), p.6959-6966
12.
13.
Tuberculosis biomarkers discovery: developments, needs, and challenges
by Wallis, Robert S, Prof
The Lancet infectious diseases, 2013, Vol.13 (4), p.362-372
14.
15.
A recombinant adenovirus expressing immunodominant TB antigens can significantly enhance BCG-induced human immunity
by Hoft, Daniel F
Vaccine, 2012, Vol.30 (12), p.2098-2108
16.
Protective efficacy of a lipid antigen vaccine in a guinea pig model of tuberculosis
by Larrouy-Maumus, Gérald
Vaccine, 2017, Vol.35 (10), p.1395-1402
17.
18.
An adult zebrafish model for preclinical tuberculosis vaccine development
by Oksanen, Kaisa E
Vaccine, 2013, Vol.31 (45), p.5202-5209
19.
A novel nanoemulsion vaccine induces mucosal Interleukin-17 responses and confers protection upon Mycobacterium tuberculosis challenge in mice
by Ahmed, Mushtaq
Vaccine, 2017, Vol.35 (37), p.4983-4989
20.
Fact and fiction in tuberculosis vaccine research: 10 years later
by Kaufmann, Stefan HE, Dr
The Lancet infectious diseases, 2011, Vol.11 (8), p.633-640
